S. Wise

发表

Nosocomial Transmission of Mycobacterium tuberculosis From an Extrapulmonary Site

E. D’Agata, Sharon E. Wise, L. Lefkowitz, 2001, Infection Control & Hospital Epidemiology.

Design and Validation of a Survey Questionnaire for the Assessment of Physician Transfusion Medicine Knowledge

S. Wise, G. Passmore, Ibsa Abdi, 2017, American Society for Clinical Laboratory Science.

AXL regulates mesothelioma proliferation and invasiveness

J. Fletcher, D. Sugarbaker, R. Bueno, 2011, Oncogene.

Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.

A. Sabichi, M. Birrer, S. Kim, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

J. Condeelis, Xiaoming Chen, Joan G. Jones, 2017, Molecular Cancer Therapeutics.

The Selective Tie 2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie 2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

J. Condeelis, Xiaoming Chen, Joan G. Jones, 2017 .

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

R. A. Etten, C. Walz, W. W. Chan, 2008 .

Discovery of Acyl Ureas as Highly Selective Small Molecule CSF1R Kinase Inhibitors.

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Clinical manifestations of human parvovirus B19 in adults.

A. Woolf, A. Woolf, P. Dieppe, 1989, Archives of internal medicine.

Identification of domains of c-Jun mediating androgen receptor transactivation

M. Birrer, S. Wise, L. Shemshedini, 1998, Oncogene.

Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Neoplastic Mast Cell Proliferation and Mast Cell Activation

G. Bandara, D. Metcalfe, O. Simakova, 2012, Leukemia.

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.

T. Leff, M. Wang, T. Su, 1999, Diabetes.

Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models

Michael D. Kaufman, D. Flynn, S. Wise, 2015 .

c-Jun Can Mediate Androgen Receptor-induced Transactivation*

S. Wise, L. Shemshedini, X. Shen, 1996, The Journal of Biological Chemistry.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

R. Larson, K. Bhalla, O. Rosen, 2016, Haematologica.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

L. Stewart, R. V. van Etten, T. Haack, 2011, Cancer cell.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Stacie L. Bulfer, O. Rosen, M. Heinrich, 2019, Cancer cell.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

B. Druker, M. Deininger, J. Tyner, 2011, Cancer research.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

L. Stewart, Michael D. Kaufman, D. Flynn, 2015, Molecular Cancer Therapeutics.

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.

Michael D. Kaufman, Hidong Kim, M. Feese, 2010, Bioorganic & medicinal chemistry letters.

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

P. Brown, A. Sabichi, M. Birrer, 1999, Oncogene.

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Michael D. Kaufman, L. Davis, R. Ruiz-Soto, 2021, Molecular Cancer Therapeutics.

16 Bacterial Stress Response

E. Ron, S. Wise, 2013 .

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

X. Shen, T. Leff, R. Vanbogelen, 2000, Diabetes.

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation

M. Berger, H. Kantarjian, J. Cortes, 2011 .

A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036

S. Redaelli, C. Gambacorti-Passerini, R. Piazza, 2010 .

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

C. Peng, R. A. Etten, Shaoguang Li, 2007 .

Analysis of recurrent research pathways for assessing and improving effectiveness in life sciences laboratories

E. Balas, S. Wise, Tiana Curry, 2023, medRxiv.

Simultaneous screening of multiple bacterial tRNA synthetases using an Escherichia coli S30-based transcription and translation assay.

T. Holler, S. Wise, M. Dermyer, 2007, Assay and drug development technologies.

Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models

M. Heinrich, Michael D. Kaufman, D. Flynn, 2015 .

Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models

J. Fagin, Michael D. Kaufman, D. Flynn, 2015 .

Abstract 5691: Evaluation of immunomodulatory agents in classically immunologically 'cold' cancers using syngeneic mouse models of breast and ovarian cancer

D. Draper, D. Daniel, Kevin Guley, 2018, Immunology.

Sequential Assessment of Troponin in the Diagnosis of Myocardial Infarction

L. Pretlow, S. Wise, G. Passmore, 2013, American Society for Clinical Laboratory Science.